- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06118229
A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients
June 26, 2024 updated by: Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
A Prospective Observational Study to the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients
The trial was designed as a single-center non-interventional prospective observational study to explore the role and impact of wearable smart devices in perioperative NSCLC patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianxing He, M.D
- Phone Number: +86-20-83337792
- Email: drjianxing.he@gmail.com
Study Contact Backup
- Name: Wenhua Liang, M.D
- Phone Number: +86-13710249454
- Email: liangwh1987@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Wenhua Liang, M.D
- Phone Number: +86-13710249454
- Email: liangwh1987@163.com
-
Contact:
- Wenhua Liang, M.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Continuously enroll all patients with non-small cell lung cancer, histopathologically confirmed
Description
Inclusion Criteria:
- Participants must provide voluntary consent to participate in this research and possess the capacity to sign an informed consent form.
- Participants must be aged over 18 years.
- Participants must have undergone pulmonary resection surgery with a postoperative pathological confirmation of primary lung cancer.
Exclusion Criteria:
- Patient refusal to participate in this research.
- Inability to wear wearable smart monitoring devices due to various reasons.
- The pathological report suggests a non-small cell lung cancer (NSCLC) exclusion.
- History of secondary lung cancer surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
NSCLC patients wearing wearable smart devices
NSCLC patients wearing wearable smart devices while utilizing PROs for regular follow-up
|
Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative length of hospital stay
Time Frame: From time of surgery to time of discharge from the hospital (assessed up to 30 days)
|
Postoperative Length of Stay (LOS) refers to the duration of a patient's hospitalization following surgery, typically measured from the completion of the surgical procedure to the time of patient discharge.
|
From time of surgery to time of discharge from the hospital (assessed up to 30 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operative time
Time Frame: From time of the start of surgery to the end of surgery
|
Operative time is defined as the time from the start of the surgical procedure to its completion, including anesthesia induction, surgical incision, manipulation of tissues, closure, and completion of all surgical tasks.
|
From time of the start of surgery to the end of surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jianxing He, M.D, The First Affiliated Hospital of Guangzhou Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2023
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
March 31, 2026
Study Registration Dates
First Submitted
October 27, 2023
First Submitted That Met QC Criteria
November 3, 2023
First Posted (Actual)
November 7, 2023
Study Record Updates
Last Update Posted (Actual)
June 28, 2024
Last Update Submitted That Met QC Criteria
June 26, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WISP-NSCLC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Jiangxi Provincial People's HopitalNot yet recruitingNon-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer RecurrentChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Wearable smart devices and PROs
-
National Taiwan University HospitalCompletedObstructive Sleep Apnea SyndromeTaiwan
-
MetroHealth Medical CenterEnrolling by invitationTotal Knee ArthroplastyUnited States
-
Taipei Medical UniversityRecruitingSedentary Lifestyle | Social Media | Wearable Technology | Health Behavior Change | ChatbotTaiwan
-
Qilu Hospital of Shandong UniversityHuashan Hospital; First Affiliated Hospital of Chongqing Medical University; Beihang... and other collaboratorsRecruiting
-
Jing LiuHUAWEINot yet recruitingMasked HypertensionChina
-
Affiliated Hospital of Nantong UniversityRecruitingSmoking | Hypertension | Diabetes | Atrial Fibrillation | Dyslipidemia | Physical Inactivity | Obesity and OverweightChina
-
Peking University Third HospitalBeijing Municipal Health Commission; BOE Technology Group Co. Ltd.Recruiting
-
Tri-Service General HospitalRecruiting
-
McGill University Health Centre/Research Institute...CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease ExacerbationCanada
-
University Hospital, Basel, SwitzerlandCompletedAtrial Fibrillation (AF)Switzerland